Key

CDK4/6 Inhibitor Market Size, Target Population, Competitive Landscape & Market Forecasts 2023-2034 - ResearchAndMarkets.com

Retrieved on: 
Friday, February 23, 2024

The "CDK4/6 Inhibitor Market Size, Target Population, Competitive Landscape & Market Forecast - 2034" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "CDK4/6 Inhibitor Market Size, Target Population, Competitive Landscape & Market Forecast - 2034" report has been added to ResearchAndMarkets.com's offering.
  • This report delivers an in-depth understanding of CDK4/6 Inhibitor, addressable patient pool, competitive landscape, and future market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the UK, and Japan.
  • The CDK4/6 Inhibitor market report provides insights around existing treatment practices in patients with CDK4/6 Inhibitor, approved (if any) and emerging CDK4/6 Inhibitor, market share of individual therapies, patient pool eligible for treatment with CDK4/6 Inhibitor, along with current and forecasted 7MM CDK4/6 Inhibitor market size from 2020-2034 by therapies and by indication.
  • This section will include details on changing CDK4/6 Inhibitor market dynamics post initiation of clinical development activities of the inhibitor.

Janus Kinase (JAK) Inhibitor Market Size, Target Population, Competitive Landscape & Market Forecasts, 2034 - ResearchAndMarkets.com

Retrieved on: 
Thursday, February 22, 2024

The "Janus Kinase (JAK) Inhibitor Market Size, Target Population, Competitive Landscape & Market Forecast - 2034" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Janus Kinase (JAK) Inhibitor Market Size, Target Population, Competitive Landscape & Market Forecast - 2034" report has been added to ResearchAndMarkets.com's offering.
  • The Janus Kinase (JAK) Inhibitor market report provides insights around existing treatment practices in patients with Janus Kinase (JAK) Inhibitor, approved (if any) and emerging Janus Kinase (JAK) Inhibitor, market share of individual therapies, patient pool eligible for treatment with Janus Kinase (JAK) Inhibitor, along with current and forecasted 7MM Janus Kinase (JAK) Inhibitor market size from 2020-2034 by therapies and by indication.
  • Apart from a comprehensive Janus Kinase (JAK) Inhibitor competitive landscape in tabular form, the emerging KRAS Inhibitor chapters provides the product details and other development activities of the emerging Janus Kinase (JAK) Inhibitor under the late and mid-stage of clinical development for various indications.
  • This section will include details on changing Janus Kinase (JAK) Inhibitor market dynamics post initiation of clinical development activities of the inhibitor.

GaN Electronics Patent Landscape Analysis Report 2023 with Database of 15,000 Patent Families - ResearchAndMarkets.com

Retrieved on: 
Wednesday, February 21, 2024

Such generic inventions were categorized as "Not specified" and were analyzed in both power and RF GaN IP landscapes:

Key Points: 
  • Such generic inventions were categorized as "Not specified" and were analyzed in both power and RF GaN IP landscapes:
    In the power GaN IP landscape, we analyzed all power GaN patents and generic GaN electronics patents from IP players owning power GaN patents, resulting in a corpus of more than 10,000 patent families (inventions).
  • In the RF GaN IP landscape, we analyzed all RF GaN patents and generic GaN electronics patents from IP players owning RF GaN patents, resulting in a corpus of more than 6,500 patent families (inventions).
  • The report details the complex relationships between GaN electronics IP players (patent co-filings, patent transfers and patent litigations).
  • GaN Electronics (Power & RF applications) - From materials to devices, modules & circuits: Patent Landscape Analysis
    Excel database containing all patents analyzed in the report (>15,000 patent families), including segmentations + hyperlink to updated online database (legal status, documents etc.)

Join Mouser Electronics at APEC 2024 for the Latest in Power Technologies and Solutions

Retrieved on: 
Tuesday, February 20, 2024

Mouser Electronics , Inc., the authorized global distributor with the newest electronic components and industrial automation products, announces that it is exhibiting at this year's Applied Power Electronics Conference and Exposition (APEC 2024) — the premier event in applied power electronics — at Booth #1213.

Key Points: 
  • Mouser Electronics , Inc., the authorized global distributor with the newest electronic components and industrial automation products, announces that it is exhibiting at this year's Applied Power Electronics Conference and Exposition (APEC 2024) — the premier event in applied power electronics — at Booth #1213.
  • View the full release here: https://www.businesswire.com/news/home/20240220590825/en/
    Mouser is exhibiting as a Platinum Partner at the 2024 Applied Power Electronics Conference and Exposition (APEC 2024) (Graphic: Business Wire)
    This year's APEC event takes place February 25–29 at the Long Beach Convention and Entertainment Center in Long Beach, CA.
  • Mouser will provide exciting and interactive information about the latest power management solutions, new product advancements, and component innovations from leading manufacturers.
  • APEC is an annual technology event that focuses on the practical and applied aspects of the power electronics industry, as well as new power electronics components.

Asceneuron Expands Scientific Advisory Board with World Leading Experts in Neurodegenerative Diseases

Retrieved on: 
Wednesday, March 6, 2024

LAUSANNE, Switzerland and SAN FRANCISCO, March 6, 2024 /PRNewswire/ -- Asceneuron SA, a clinical stage biotech company dedicated to targeting the root causes of neurodegenerative diseases, today announces the appointments of neurodegenerative disease experts to its Scientific Advisory Board (SAB).

Key Points: 
  • LAUSANNE, Switzerland and SAN FRANCISCO, March 6, 2024 /PRNewswire/ -- Asceneuron SA, a clinical stage biotech company dedicated to targeting the root causes of neurodegenerative diseases, today announces the appointments of neurodegenerative disease experts to its Scientific Advisory Board (SAB).
  • Asceneuron is advancing development of its lead asset ASN51 into Phase II clinical development targeting Alzheimer's disease.
  • The Scientific Advisory Board members have vast experience in clinical trial design and biomarkers and will help support this promising program through Phase II clinical development.
  • I am honored to have these stellar neurodegenerative experts join our SAB at a fundamental time of development.

Asceneuron Expands Scientific Advisory Board with World Leading Experts in Neurodegenerative Diseases

Retrieved on: 
Wednesday, March 6, 2024

LAUSANNE, Switzerland and SAN FRANCISCO, March 6, 2024 /PRNewswire/ -- Asceneuron SA, a clinical stage biotech company dedicated to targeting the root causes of neurodegenerative diseases, today announces the appointments of neurodegenerative disease experts to its Scientific Advisory Board (SAB).

Key Points: 
  • LAUSANNE, Switzerland and SAN FRANCISCO, March 6, 2024 /PRNewswire/ -- Asceneuron SA, a clinical stage biotech company dedicated to targeting the root causes of neurodegenerative diseases, today announces the appointments of neurodegenerative disease experts to its Scientific Advisory Board (SAB).
  • Asceneuron is advancing development of its lead asset ASN51 into Phase II clinical development targeting Alzheimer's disease.
  • The Scientific Advisory Board members have vast experience in clinical trial design and biomarkers and will help support this promising program through Phase II clinical development.
  • I am honored to have these stellar neurodegenerative experts join our SAB at a fundamental time of development.

Experts in Tech and Politics Merge to Launch Needle PR: The Communications Agency that Makes A Point

Retrieved on: 
Friday, March 1, 2024

NEW YORK, March 1, 2024 /PRNewswire-PRWeb/ -- Needle, the communications agency that makes a point, announced its launch today.

Key Points: 
  • New agency applies cross-industry expertise to move the needle for companies, venture funds, and movements shaping our world
    NEW YORK, March 1, 2024 /PRNewswire-PRWeb/ -- Needle , the communications agency that makes a point, announced its launch today.
  • That's why our guiding principle is 'make a point' – we get to the heart of why you matter.
  • Needle will focus on finding the common thread that connects clients to stories that matter and advance their goals.
  • Needle provides a full range of services from communications strategy and media relations to content development and thought leadership.

Drata Achieves Strong Growth, Defying Technology Market Challenges while Solidifying Leadership in Compliance Automation

Retrieved on: 
Wednesday, February 21, 2024

SAN DIEGO, Feb. 21, 2024 /PRNewswire/ -- Drata, the leading continuous security and compliance automation platform, extended strong momentum into the 2024 fiscal year, completed in January. On the heels of the company's three-year anniversary, Drata's milestones include supporting 10 new frameworks and 100% revenue growth. Streamlining risk and compliance for companies such as Calendly, SmartRecruiters, and Distology, Drata's remarkable global expansion surpassed 4,000+ customers across 50+ countries. The company also cemented its leadership status in G2's Cloud Compliance category, and ranked in the top 30 for G2's 2024 Top 100 Best Software Products list.

Key Points: 
  • Streamlining risk and compliance for companies such as Calendly, SmartRecruiters, and Distology, Drata's remarkable global expansion surpassed 4,000+ customers across 50+ countries.
  • The company also cemented its leadership status in G2's Cloud Compliance category, and ranked in the top 30 for G2's 2024 Top 100 Best Software Products list.
  • Business milestones for Drata's fiscal year include:
    100% Year-over-Year (YoY) in new revenue growth, with up to 650 new customers added each quarter.
  • "Three years in, Drata has transformed security compliance for 1.2 million users, becoming the go-to source for building and maintaining trust," said Adam Markowitz, Drata Co-Founder and CEO.

Green Hydrogen Industry Leader Denis Krude Appointed President & CEO of Hydrogen Optimized

Retrieved on: 
Wednesday, February 21, 2024

OWEN SOUND, ON, Feb. 21, 2024 /PRNewswire/ -- Hydrogen Optimized Inc., a subsidiary of Key DH Technologies Inc. (KEY), today announced that Denis Krude, former CEO of green hydrogen technology company thyssenkrupp nucera, will be appointed President and CEO starting April 8, 2024. Company Co-Founder Andrew Stuart will continue to play an active leadership role at Hydrogen Optimized as Executive Chair.

Key Points: 
  • OWEN SOUND, ON, Feb. 21, 2024 /PRNewswire/ -- Hydrogen Optimized Inc., a subsidiary of Key DH Technologies Inc. (KEY), today announced that Denis Krude, former CEO of green hydrogen technology company thyssenkrupp nucera, will be appointed President and CEO starting April 8, 2024.
  • Company Co-Founder Andrew Stuart will continue to play an active leadership role at Hydrogen Optimized as Executive Chair.
  • "I am delighted that Denis has chosen to join the Hydrogen Optimized team as CEO as we enter an exciting new phase of our company's commercial development," said Andrew Stuart, founding President and CEO of Hydrogen Optimized.
  • "With proven executive experience in the sale and deployment of green hydrogen production plants, Denis is uniquely well-positioned to lead our company in the emerging large-scale clean hydrogen technology market.

World GaN Electronics Patent Landscape Analysis Report 2023: Focus on Patenting Activity of US, Japanese, Chinese, European, South Korean and Taiwanese Entities

Retrieved on: 
Wednesday, February 21, 2024

DUBLIN, Feb. 20, 2024 /PRNewswire/ -- The "GaN Electronics Patent Landscape Analysis 2023" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, Feb. 20, 2024 /PRNewswire/ -- The "GaN Electronics Patent Landscape Analysis 2023" report has been added to ResearchAndMarkets.com's offering.
  • In the RF GaN IP landscape, we analyzed all RF GaN patents and generic GaN electronics patents from IP players owning RF GaN patents, resulting in a corpus of more than 6,500 patent families (inventions).
  • The report details the complex relationships between GaN electronics IP players (patent co-filings, patent transfers and patent litigations).
  • Providing a detailed picture of the different GaN ecosystems focusing on the patenting activity of US, Japanese, Chinese, European, South Korean and Taiwanese entities.